TG Therapeutics (TGTX)
Market Price (5/9/2026): $42.88 | Market Cap: $6.2 BilSector: Health Care | Industry: Biotechnology
TG Therapeutics (TGTX)
Market Price (5/9/2026): $42.88Market Cap: $6.2 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 7.5%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.1% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 81% Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 21% Low stock price volatilityVol 12M is 46% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Trading close to highsDist 52W High is -0.4% Weak multi-year price returns3Y Excs Rtn is -58% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 20% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 41x Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -2.0%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -2.0% Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 19.11 Key risksTGTX key risks include [1] its heavy revenue concentration on a single commercial product, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 7.5%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.1% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 81% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 21% |
| Low stock price volatilityVol 12M is 46% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Trading close to highsDist 52W High is -0.4% |
| Weak multi-year price returns3Y Excs Rtn is -58% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 20% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 41x |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -2.0%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -2.0% |
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 19.11 |
| Key risksTGTX key risks include [1] its heavy revenue concentration on a single commercial product, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Strong Q1 2026 Revenue and Increased Full-Year Guidance for BRIUMVI.
TG Therapeutics reported first-quarter 2026 revenue of $204.92 million, surpassing analyst estimates of $200.75 million. U.S. net revenue from their flagship drug, BRIUMVI, reached approximately $195 million in Q1, exceeding the company's guidance of $185 million-$190 million and marking a 63% increase year-over-year. This strong performance led the company to raise its full-year U.S. revenue guidance for BRIUMVI to $885 million-$900 million.
2. Positive Analyst Sentiment and Upward Price Target Revisions.
The company has received favorable analyst coverage, with a consensus rating of "Moderate Buy" or "Strong Buy" and an average 1-year price target ranging from $41.25 to $51.8 across various firms. Notably, HC Wainwright & Co. set a price target of $70.00 on May 6, 2026, suggesting a potential upside of 69.08%. Additionally, JPMorgan maintained an "Overweight" rating with a $46.00 price target on February 2, 2026.
Show more
Stock Movement Drivers
Fundamental Drivers
The 45.6% change in TGTX stock from 1/31/2026 to 5/8/2026 was primarily driven by a 40.1% change in the company's P/E Multiple.| (LTM values as of) | 1312026 | 5082026 | Change |
|---|---|---|---|
| Stock Price ($) | 29.43 | 42.86 | 45.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 532 | 700 | 31.7% |
| Net Income Margin (%) | 84.1% | 66.0% | -21.6% |
| P/E Multiple | 9.6 | 13.4 | 40.1% |
| Shares Outstanding (Mil) | 145 | 144 | 0.7% |
| Cumulative Contribution | 45.6% |
Market Drivers
1/31/2026 to 5/8/2026| Return | Correlation | |
|---|---|---|
| TGTX | 45.6% | |
| Market (SPY) | 3.6% | 43.7% |
| Sector (XLV) | -6.9% | 26.8% |
Fundamental Drivers
The 23.2% change in TGTX stock from 10/31/2025 to 5/8/2026 was primarily driven by a 395.3% change in the company's Net Income Margin (%).| (LTM values as of) | 10312025 | 5082026 | Change |
|---|---|---|---|
| Stock Price ($) | 34.78 | 42.86 | 23.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 454 | 700 | 54.2% |
| Net Income Margin (%) | 13.3% | 66.0% | 395.3% |
| P/E Multiple | 84.4 | 13.4 | -84.1% |
| Shares Outstanding (Mil) | 147 | 144 | 1.6% |
| Cumulative Contribution | 23.2% |
Market Drivers
10/31/2025 to 5/8/2026| Return | Correlation | |
|---|---|---|
| TGTX | 23.2% | |
| Market (SPY) | 5.5% | 25.0% |
| Sector (XLV) | 0.3% | 28.1% |
Fundamental Drivers
The -5.8% change in TGTX stock from 4/30/2025 to 5/8/2026 was primarily driven by a -95.3% change in the company's P/E Multiple.| (LTM values as of) | 4302025 | 5082026 | Change |
|---|---|---|---|
| Stock Price ($) | 45.51 | 42.86 | -5.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 329 | 700 | 112.9% |
| Net Income Margin (%) | 7.1% | 66.0% | 828.0% |
| P/E Multiple | 282.7 | 13.4 | -95.3% |
| Shares Outstanding (Mil) | 145 | 144 | 0.6% |
| Cumulative Contribution | -5.8% |
Market Drivers
4/30/2025 to 5/8/2026| Return | Correlation | |
|---|---|---|
| TGTX | -5.8% | |
| Market (SPY) | 30.4% | 20.8% |
| Sector (XLV) | 4.0% | 25.0% |
Fundamental Drivers
The 72.6% change in TGTX stock from 4/30/2023 to 5/8/2026 was primarily driven by a 25056.2% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302023 | 5082026 | Change |
|---|---|---|---|
| Stock Price ($) | 24.83 | 42.86 | 72.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 700 | 25056.2% |
| P/S Multiple | 1,223.0 | 8.8 | -99.3% |
| Shares Outstanding (Mil) | 137 | 144 | -5.1% |
| Cumulative Contribution | 72.6% |
Market Drivers
4/30/2023 to 5/8/2026| Return | Correlation | |
|---|---|---|
| TGTX | 72.6% | |
| Market (SPY) | 78.7% | 19.7% |
| Sector (XLV) | 13.0% | 20.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| TGTX Return | -63% | -38% | 44% | 76% | -1% | 44% | -17% |
| Peers Return | 13% | 20% | -4% | 1% | 23% | 3% | 67% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 95% |
Monthly Win Rates [3] | |||||||
| TGTX Win Rate | 33% | 33% | 50% | 58% | 42% | 80% | |
| Peers Win Rate | 52% | 55% | 42% | 53% | 58% | 48% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| TGTX Max Drawdown | -71% | -80% | -44% | -24% | -12% | -10% | |
| Peers Max Drawdown | -7% | -9% | -19% | -18% | -11% | -5% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BIIB, GILD, BMY, AMGN, ABBV. See TGTX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/8/2026 (YTD)
How Low Can It Go
| Event | TGTX | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -16.0% | -7.8% |
| % Gain to Breakeven | 19.1% | 8.5% |
| Time to Breakeven | 1 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -66.8% | -9.5% |
| % Gain to Breakeven | 201.5% | 10.5% |
| Time to Breakeven | 81 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -23.4% | -6.7% |
| % Gain to Breakeven | 30.6% | 7.1% |
| Time to Breakeven | 31 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -81.7% | -24.5% |
| % Gain to Breakeven | 446.8% | 32.4% |
| Time to Breakeven | 299 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -55.3% | -33.7% |
| % Gain to Breakeven | 123.9% | 50.9% |
| Time to Breakeven | 48 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -36.4% | -19.2% |
| % Gain to Breakeven | 57.3% | 23.7% |
| Time to Breakeven | 66 days | 105 days |
In The Past
TG Therapeutics's stock fell -8.0% during the 2025 US Tariff Shock. Such a loss loss requires a 8.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | TGTX | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -66.8% | -9.5% |
| % Gain to Breakeven | 201.5% | 10.5% |
| Time to Breakeven | 81 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -23.4% | -6.7% |
| % Gain to Breakeven | 30.6% | 7.1% |
| Time to Breakeven | 31 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -81.7% | -24.5% |
| % Gain to Breakeven | 446.8% | 32.4% |
| Time to Breakeven | 299 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -55.3% | -33.7% |
| % Gain to Breakeven | 123.9% | 50.9% |
| Time to Breakeven | 48 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -36.4% | -19.2% |
| % Gain to Breakeven | 57.3% | 23.7% |
| Time to Breakeven | 66 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -46.8% | -3.7% |
| % Gain to Breakeven | 88.1% | 3.9% |
| Time to Breakeven | 45 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -51.0% | -12.2% |
| % Gain to Breakeven | 104.2% | 13.9% |
| Time to Breakeven | 765 days | 62 days |
| 2013 Taper Tantrum | ||
| % Loss | -42.4% | -0.2% |
| % Gain to Breakeven | 73.5% | 0.2% |
| Time to Breakeven | 67 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -89.2% | -17.9% |
| % Gain to Breakeven | 827.1% | 21.8% |
| Time to Breakeven | 111 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -94.0% | -53.4% |
| % Gain to Breakeven | 1571.7% | 114.4% |
| Time to Breakeven | 183 days | 1085 days |
In The Past
TG Therapeutics's stock fell -8.0% during the 2025 US Tariff Shock. Such a loss loss requires a 8.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About TG Therapeutics (TGTX)
AI Analysis | Feedback
- A biotech company developing various cancer and autoimmune treatments, including their own version of a Keytruda-like immunotherapy.
- Like a nimble Genentech or Bristol Myers Squibb, they develop advanced antibody therapies and targeted drugs for blood cancers and autoimmune diseases.
AI Analysis | Feedback
Major Products of TG Therapeutics (TGTX):
- Ublituximab: An investigational glycoengineered monoclonal antibody for B-cell non-hodgkin lymphoma, CLL, and relapsing forms of multiple sclerosis.
- Umbralisib: An oral inhibitor for CLL, marginal zone lymphoma, and follicular lymphoma.
- Cosibelimab: A human monoclonal antibody that binds to PD-L1, blocking its interactions with PD-1 and B7.1 receptors.
- TG-1701: An orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor.
- TG-1801: A bispecific CD47 and CD19 antibody.
AI Analysis | Feedback
TG Therapeutics (symbol: TGTX), as a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutic treatments, primarily sells its products to other companies within the healthcare supply chain rather than directly to individuals. Based on the provided company description, specific names of major customer companies are not disclosed. However, consistent with the business model of a biopharmaceutical company, its major customers would typically fall into the following categories:- Major Pharmaceutical Wholesalers: These companies purchase drugs directly from manufacturers like TG Therapeutics and then distribute them to various healthcare providers, including pharmacies, hospitals, and clinics.
- Hospitals and Healthcare Systems: These institutions purchase pharmaceutical products for use in inpatient and outpatient settings, particularly for treatments requiring administration in a clinical environment (e.g., infusions).
- Specialty Pharmacies: For complex, high-cost, or niche medications that often require specialized handling, storage, or patient support services, specialty pharmacies serve as key purchasers and distributors.
AI Analysis | Feedback
```html- Checkpoint Therapeutics, Inc. (CKPT)
- Ligand Pharmaceuticals Incorporated (LGND)
- LFB Biotechnologies S.A.S
- Rhizen Pharmaceuticals, S A
AI Analysis | Feedback
Michael S. Weiss, Chairman, President, and Chief Executive Officer
Michael S. Weiss founded TG Therapeutics and has served as its Chairman, President, and CEO since December 2011. Prior to TG, he founded and was CEO of ACCESS Oncology in 1999, which later merged with Keryx Biopharmaceuticals in 2004. He served as Chairman and CEO of Keryx Biopharmaceuticals until mid-2009, during which time he acquired and developed AURYXIA, and led efforts to develop Zerenex and executed a strategic alliance for it. Before founding ACCESS Oncology, Mr. Weiss spent several years as a lawyer at Cravath, Swaine & Moore and then as an investor in biotech venture capital. He also serves as Vice Chairman of Fortress Biotech, Chairman of Checkpoint Therapeutics and Mustang Bio, and is a Partner at Opus Point Partners Management LLC.
Sean A. Power, CPA, Chief Financial Officer
Sean A. Power has served as TG Therapeutics' Chief Financial Officer, Treasurer, and Corporate Secretary since December 2011. Before joining TG, he was the Corporate Controller at Keryx Biopharmaceuticals, Inc. from 2006 to 2011, where he was involved in capital raising and licensing transactions and responsible for SEC compliance. Earlier in his career, he was a senior associate at KPMG, LLP. Mr. Power also serves as CFO of Opus Point Partners.
Adam Waldman, Chief Commercialization Officer
Adam Waldman joined TG Therapeutics in June 2018 as Chief Commercialization Officer. He previously spent thirteen years at Celgene Corporation, most recently as Head of Hematology-Oncology Marketing, holding various roles in sales, marketing, and new product strategy. Prior to Celgene, Mr. Waldman was at Schering Plough, where he managed the global marketing strategy for multiple oncology products.
Hari Miskin, Chief Development Officer
Hari Miskin serves as the Chief Development Officer of TG Therapeutics, Inc.
Jenna Bosco, Senior Vice President of Corporate Communications
Jenna Bosco serves as the Senior Vice President of Corporate Communications for TG Therapeutics. She is also identified as Director of Investor Relations and Chief Communications Officer.
AI Analysis | Feedback
TG Therapeutics (TGTX) faces several key risks to its business, primarily stemming from the inherent challenges of the biopharmaceutical industry, particularly concerning regulatory approvals, market commercialization, and pipeline development. These risks are ordered from most to least significant.
1. Regulatory Setbacks and Product Withdrawals
A significant risk that has already materialized for TG Therapeutics is the withdrawal of its cancer medicine, Umbralisib (UKONIQ). In June 2022, the U.S. Food and Drug Administration (FDA) withdrew its approval for Umbralisib for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL) due to safety concerns, specifically an observed increased risk of death in patients receiving the drug. This withdrawal also led to the voluntary cessation of the company's application for the combination of ublituximab and umbralisib (U2) for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in April 2022. This event underscores the substantial regulatory and safety risks inherent in drug development and commercialization, which can lead to the loss of approved products and significant financial impact.
2. High Dependency on BRIUMVI and Commercialization Challenges
Following the withdrawal of Umbralisib, TG Therapeutics' financial well-being is heavily reliant on the commercial success of its remaining key product, BRIUMVI (ublituximab-xiiy). BRIUMVI received FDA approval in December 2022 for the treatment of relapsing forms of multiple sclerosis (RMS) and is also approved in several ex-US territories. While the company is actively focused on its commercialization and expanding its market reach, including developing a subcutaneous version, this high dependency on a single product exposes the company to significant commercialization risks. These risks include intense competition within the MS market, potential issues with market acceptance, unfavorable pricing or reimbursement policies, and any unforeseen safety concerns that could emerge post-market.
3. Future Regulatory and Development Risks for Pipeline Products
TG Therapeutics' long-term growth is tied to the successful development and regulatory approval of its remaining pipeline candidates, which include investigational medicines such as Cosibelimab, TG-1701, and TG-1801, as well as various preclinical programs. Although Cosibelimab (an anti-PD-L1 antibody) has received FDA approval for metastatic or locally advanced cutaneous squamous cell carcinoma, the broader pipeline still faces significant hurdles. The biopharmaceutical industry is characterized by high costs, lengthy development timelines, and a low probability of success in clinical trials. Failures to achieve positive clinical trial results or secure regulatory approvals for these candidates could severely impact the company's ability to diversify its revenue streams and achieve sustainable growth. The company also faces an ongoing need for substantial capital to fund its operations and research efforts, adding a financial risk dimension to its development programs.
AI Analysis | Feedback
nullAI Analysis | Feedback
TG Therapeutics (TGTX) Addressable Markets for Main Products
-
Ublituximab (BRIUMVI)
- For conditions such as relapsing forms of multiple sclerosis (RMS), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL):
- The global ublituximab market size was estimated at $1.11 billion in 2024 and is projected to grow to $1.25 billion in 2025, reaching $2.0 billion by 2029 with a compound annual growth rate (CAGR) of 12.4%. This market is driven by increasing demand for targeted therapies and the rising incidence of autoimmune disorders.
- For conditions such as relapsing forms of multiple sclerosis (RMS), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL):
-
Umbralisib (Ukoniq)
- The U.S. Food and Drug Administration (FDA) withdrew its approval for Umbralisib (Ukoniq) in June 2022 due to safety concerns, specifically for marginal zone lymphoma (MZL) and follicular lymphoma (FL). TG Therapeutics also voluntarily withdrew its biologics license application and supplemental new drug application for Umbralisib plus Ublituximab for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in April 2022. Therefore, there is currently no addressable market for Umbralisib as a standalone product or in combination in the U.S. for these indications.
-
Cosibelimab (Unloxcyt)
- For metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) in adults who are not candidates for curative surgery or curative radiation:
- The U.S. market opportunity for cutaneous squamous cell carcinoma (CSCC) was estimated at $1.6 billion.
- The global cutaneous squamous cell carcinoma (CSCC) treatment market size was estimated at $13.69 billion in 2024, projected to grow to $14.68 billion in 2025, and is expected to reach approximately $27.54 billion by 2034. North America led this market in 2024.
- For metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) in adults who are not candidates for curative surgery or curative radiation:
AI Analysis | Feedback
TG Therapeutics (TGTX) has several anticipated drivers for future revenue growth over the next 2-3 years, primarily centered around its approved products and pipeline advancements:
- Continued U.S. Sales Growth of BRIUMVI (Ublituximab) in Relapsing Multiple Sclerosis (RMS): BRIUMVI, the company's flagship product for relapsing forms of multiple sclerosis, is expected to continue its strong sales trajectory. In 2025, U.S. net sales of BRIUMVI reached $594 million, reflecting approximately 92% year-over-year growth. TG Therapeutics has provided 2026 U.S. net revenue guidance for BRIUMVI between $825 million and $850 million. This growth is anticipated to be driven by increasing prescriber adoption, market share gains, and high patient persistence on therapy.
- Global Expansion of BRIUMVI: Beyond the U.S., BRIUMVI's commercialization has expanded internationally. The treatment has secured regulatory approvals in key markets including the European Union, United Kingdom, Switzerland, Australia, Kuwait, and the United Arab Emirates. This global rollout, facilitated by partnerships such as with Neuraxpharm, is expected to contribute significantly to TG Therapeutics' total global revenue.
- Launch and Adoption of Subcutaneous BRIUMVI: TG Therapeutics is developing a self-administered subcutaneous formulation of BRIUMVI. Pivotal data for this subcutaneous version is projected to be available by late 2026 or early 2027, with a potential launch in 2028. A subcutaneous option could substantially broaden the addressable market by offering a more convenient, at-home administration, thereby accelerating revenue growth.
- Introduction of a Consolidated Intravenous Dosing Regimen for BRIUMVI: The company has completed enrollment for the Phase 3 ENHANCE study, which evaluates a consolidated intravenous (IV) dosing schedule for BRIUMVI. Topline data from this study are expected in mid-2026, with a potential launch of the simplified infusion protocol anticipated in 2027. This improved dosing regimen aims to enhance convenience for patients and healthcare providers, further boosting market share.
- Commercialization of Cosibelimab for Cutaneous Squamous Cell Carcinoma (cSCC): Cosibelimab (Unloxcyt), a PD-L1 antibody, received FDA approval in December 2024 for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or radiation. As a newly approved product, Cosibelimab represents an important new revenue stream for TG Therapeutics, addressing an unmet need in the cSCC treatment landscape.
AI Analysis | Feedback
Share Repurchases
- TG Therapeutics completed a $100 million share repurchase program, initially announced in August 2024.
- Under the completed program, the company repurchased approximately 3.5 million shares of its common stock at an average price of $28.55 per share.
- The Board of Directors authorized a new share repurchase program to acquire up to an additional $100 million of common stock in September 2025.
Inbound Investments
- Public Sector Pension Investment Board increased its stake in TG Therapeutics by 14.5%, holding 529,271 shares valued at approximately $19.12 million as of the third quarter of a recent reporting period.
- Jump Financial LLC boosted its holdings in the company by 551.8%, acquiring an additional 270,922 shares to own 320,022 shares worth $11.518 million in the second quarter.
- Eventide Asset Management LLC increased its holdings by 32.8% in the second quarter, bringing its total to 954,531 shares valued at $34.354 million.
Capital Expenditures
- TG Therapeutics reported capital expenditures of $0.21 million in 2025.
- In the fourth quarter of 2025, the company invested $67K in capital expenditures, focusing on funding long-term assets and infrastructure.
- For 2026, the company anticipates approximately $100 million in expenses associated with subcutaneous BRIUMVI manufacturing costs and secondary manufacturer start-up costs.
Latest Trefis Analyses
Trade Ideas
Select ideas related to TGTX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 03062026 | TGTX | TG Therapeutics | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 15.4% | 15.4% | -8.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 162.39 |
| Mkt Cap | 138.8 |
| Rev LTM | 33,477 |
| Op Inc LTM | 11,234 |
| FCF LTM | 9,414 |
| FCF 3Y Avg | 9,097 |
| CFO LTM | 10,781 |
| CFO 3Y Avg | 10,116 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.0% |
| Rev Chg 3Y Avg | 2.6% |
| Rev Chg Q | 5.1% |
| QoQ Delta Rev Chg LTM | 1.1% |
| Op Inc Chg LTM | 55.4% |
| Op Inc Chg 3Y Avg | 9.2% |
| Op Mgn LTM | 28.2% |
| Op Mgn 3Y Avg | 23.4% |
| QoQ Delta Op Mgn LTM | 0.8% |
| CFO/Rev LTM | 28.2% |
| CFO/Rev 3Y Avg | 29.9% |
| FCF/Rev LTM | 23.9% |
| FCF/Rev 3Y Avg | 26.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 138.8 |
| P/S | 5.1 |
| P/Op Inc | 15.3 |
| P/EBIT | 15.1 |
| P/E | 19.2 |
| P/CFO | 13.0 |
| Total Yield | 7.4% |
| Dividend Yield | 2.7% |
| FCF Yield 3Y Avg | 6.6% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -4.5% |
| 3M Rtn | -8.8% |
| 6M Rtn | 17.4% |
| 12M Rtn | 26.2% |
| 3Y Rtn | 42.1% |
| 1M Excs Rtn | -13.4% |
| 3M Excs Rtn | -15.5% |
| 6M Excs Rtn | 7.1% |
| 12M Excs Rtn | -7.5% |
| 3Y Excs Rtn | -44.2% |
Comparison Analyses
Price Behavior
| Market Price | $42.86 | |
| Market Cap ($ Bil) | 5.9 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -0.4% | |
| 50 Days | 200 Days | |
| DMA Price | $33.08 | $31.92 |
| DMA Trend | indeterminate | up |
| Distance from DMA | 29.5% | 34.3% |
| 3M | 1YR | |
| Volatility | 53.4% | 46.0% |
| Downside Capture | -0.15 | 0.27 |
| Upside Capture | 159.85 | 66.22 |
| Correlation (SPY) | 31.9% | 18.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.03 | 1.40 | 1.26 | 0.77 | 0.76 | 0.89 |
| Up Beta | 2.09 | 1.58 | 1.57 | 1.49 | 0.60 | 0.59 |
| Down Beta | 3.75 | 0.63 | 0.51 | 0.06 | 0.55 | 0.66 |
| Up Capture | 112% | 190% | 168% | 69% | 49% | 167% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 12 | 22 | 32 | 64 | 127 | 372 |
| Down Capture | 277% | 114% | 105% | 74% | 115% | 107% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 10 | 21 | 32 | 61 | 124 | 378 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TGTX | |
|---|---|---|---|---|
| TGTX | 24.2% | 46.1% | 0.61 | - |
| Sector ETF (XLV) | 7.9% | 15.4% | 0.30 | 24.5% |
| Equity (SPY) | 29.0% | 12.5% | 1.83 | 20.5% |
| Gold (GLD) | 39.8% | 27.0% | 1.22 | 15.2% |
| Commodities (DBC) | 50.6% | 18.0% | 2.21 | -8.1% |
| Real Estate (VNQ) | 13.0% | 13.5% | 0.66 | 26.5% |
| Bitcoin (BTCUSD) | -17.9% | 42.1% | -0.35 | 12.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TGTX | |
|---|---|---|---|---|
| TGTX | -0.0% | 87.7% | 0.40 | - |
| Sector ETF (XLV) | 4.9% | 14.6% | 0.16 | 27.9% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 35.7% |
| Gold (GLD) | 20.9% | 17.9% | 0.95 | 8.9% |
| Commodities (DBC) | 13.8% | 19.1% | 0.59 | 2.5% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 35.4% |
| Bitcoin (BTCUSD) | 6.9% | 56.0% | 0.34 | 21.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TGTX | |
|---|---|---|---|---|
| TGTX | 16.9% | 87.0% | 0.57 | - |
| Sector ETF (XLV) | 9.3% | 16.5% | 0.46 | 31.0% |
| Equity (SPY) | 15.1% | 17.9% | 0.72 | 35.4% |
| Gold (GLD) | 13.4% | 15.9% | 0.69 | 5.2% |
| Commodities (DBC) | 9.3% | 17.8% | 0.44 | 9.2% |
| Real Estate (VNQ) | 5.8% | 20.7% | 0.24 | 27.7% |
| Bitcoin (BTCUSD) | 67.7% | 66.9% | 1.07 | 13.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/26/2026 | 4.2% | -1.6% | 7.8% |
| 11/3/2025 | -3.1% | -7.3% | -9.1% |
| 8/4/2025 | -18.0% | -23.7% | -15.1% |
| 3/3/2025 | 14.4% | 27.8% | 31.0% |
| 11/4/2024 | -9.4% | 7.1% | 24.1% |
| 8/6/2024 | 19.6% | 20.0% | 28.3% |
| 2/28/2024 | 26.7% | 30.0% | 11.9% |
| 11/1/2023 | 30.9% | 40.1% | 65.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 11 | 11 |
| # Negative | 8 | 7 | 7 |
| Median Positive | 17.0% | 20.0% | 14.1% |
| Median Negative | -10.2% | -12.2% | -15.1% |
| Max Positive | 63.4% | 64.0% | 65.7% |
| Max Negative | -49.3% | -51.2% | -52.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/27/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 03/03/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 05/06/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | null |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 5/6/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q2 2026 BRIUMVI U.S. Net Product Revenue | 220.00 Mil | 17.3% | Higher New | Actual: 187.50 Mil for Q1 2026 | |||
| 2026 Total Global Revenue | 925.00 Mil | 4.2% | Raised | Guidance: 887.50 Mil for 2026 | |||
| 2026 BRIUMVI U.S. Net Product Revenue | 885.00 Mil | 892.50 Mil | 900.00 Mil | 6.6% | Raised | Guidance: 837.50 Mil for 2026 | |
| 2026 Operating Expense | 350.00 Mil | 0 | Affirmed | Guidance: 350.00 Mil for 2026 | |||
| 2026 Subcutaneous BRIUMVI Expenses | 100.00 Mil | ||||||
Prior: Q4 2025 Earnings Reported 2/26/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 BRIUMVI U.S. Net Product Revenue | 185.00 Mil | 187.50 Mil | 190.00 Mil | ||||
| 2026 Total Global Revenue | 875.00 Mil | 887.50 Mil | 900.00 Mil | 47.9% | Higher New | Guidance: 600.00 Mil for 2025 | |
| 2026 BRIUMVI U.S. Net Product Revenue | 825.00 Mil | 837.50 Mil | 850.00 Mil | 43.2% | Higher New | Guidance: 585.00 Mil for 2025 | |
| 2026 Operating Expense | 350.00 Mil | ||||||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.